Due Diligence (7)

Challenge A European pharma company needed to conduct an expert reality check on a pain in-licensing opportunity.

Challenge An established medical device company looking to make a strategic investment needed commercial, regulatory, IP and technical due diligence on an investment opportunity in the diabetes...

Challenge A major UK bioscience investor needed due diligence on a cell biology reagents investment opportunity.

Challenge An incoming lead investor needed to assess a proprietary platform technology for the oral delivery of biological drugs.

Challenge A pharma company looking to purchase an asset needed a respiratory consultant to conduct clinical due diligence of a Phase II biologic designed to treat a respiratory condition.

Challenge A well-capitalized strategic investor looking to enter the radiopharmaceuticals market wanted to conduct clinical due diligence on a novel radioisotope-conjugated antibody designed to treat...

Challenge Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the US. One target company was developing a new...

Challenge A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge A major pharma company needed scientific and immunology due diligence support on a novel cyclic peptide, targeting the complement cascade system.

Challenge A major pharmaceutical company asked us for support in the medical safety and pharmacovigilance due diligence and assessment of a Phase III in-licensing opportunity. The drug in question...

Challenge A venture capital investor needed an assessment of the technical, regulatory and market risks in a neuroscience specialty pharma company developing a range of products through the 505...

Challenge A European pharma company seeking to license a development-stage follow-on biologic needed to assess the commercial potential of a second-generation antibody against a validated oncology...